Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good
- PMID: 23047830
- DOI: 10.1136/thoraxjnl-2012-202580
Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good
Comment in
-
Idiopathic pulmonary fibrosis: is all-cause mortality a practical and realistic end-point for clinical trials?Thorax. 2013 May;68(5):491-2. doi: 10.1136/thoraxjnl-2012-203114. Epub 2013 Jan 23. Thorax. 2013. PMID: 23345573 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical